Fritextsökning
Innehållstyper
-
New CEO to Medivir
The Board of the Swedish biotech company Medivir has appointed the successor to the current CEO Lars Adlersson.
-
Swiss allergy therapy convinces
Cytos Biotechnology presents promising results in a study of a new therapy against allergy and asthma.
-
Blood type decide resistance to HIV
A Canadian-Swedish research team has found a blood type molecule that increases the resistance to HIV-infections.
-
Control of blood vessels can treat obesity
Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet.
-
Testar ny behandling av svår PMS
Umeåbolaget Umecrine Mood är halvvägs igenom fas IIa-studie med sin läkemedelskandidat mot premenstruella besvär. Nu letar forskningsbolaget efter en partner ti...
-
Finnish-Dutch engineering cooperation continues
The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.
-
Ytterligare ett stort bakslag för Alzheimerspreparat
Trots alla misslyckanden är intresset mycket stort att hitta ett läkemedel som inte bara lindrar symtomen.
-
Därför är det så svårt
15 life science-kändisar berättar i en ny bok om svårigheterna att få ut medicinska innovationer på marknaden och vad som krävs för att det ska bli lättare.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
Martin Bergö: "The Idea is the Thing"
Martin Bergö, 38, goes wherever ideas take him - it's a process that has led to, and resulted from, plenty of unexpected results. Those ideas have been recogniz...
-
Orion cuts 205 jobs
The Finnish company Orion has completed its statutory negotiations. By this, personnel will be reduced by about 205 in Finland.
-
Changing e-solutions for clinical trials
Social media and personalized medicine are two factors that will have a great impact on the design and IT-solutions for clinical trials. Unithink is an upcoming...
-
Focusing on Medicon Valley
Copenhagen Capacity and Invest in Skåne are hosting a seminar to promote the geographical area known as Medicon Valley. Some of the 350 life science companies f...
-
Infidelity produces faster sperms
Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.
-
Crafoord Prize to an American and two Japanese
Today the Royal Swedish Academy of Sciences announces the laureates of the Crafoord Prize in Polyarthritis 2009.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
SDU professor helps EU
Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.
-
Digitalisering och kliniska prövningar
Effektivare kliniska prövningar och ny teknologi för dokumentation av behandlingar - Digitaliseringen öppnar många möjligheter. Ola Björkman rapporterar från BIO i San Diego.
-
Life science mer jämställt
19 procent kvinnor i ledningsgrupperna hos de största life science-företagen.
-
Spel vägen till bättre hälsa
På Digital Health Days berättade gamificationexperter hur spel kan användas för att lösa medicinska problem och motivera folk att hålla god hälsa.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
Tusen produkter ute
Cellavision firar tio år som säljande bolag och levererar sitt tusende instrument nu i veckan.
-
Elekta gets ok from China
The Swedish medtech comapny Elekta has received approval from the Chinese authority State Food and Drug Administration, SFDA, to sell its linear accelerator in China.